Department of Surgery, Hospital de Clínicas de Porto Alegre, School of Medicine, Federal University of Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil.
Gastroenterol Res Pract. 2012;2012:639748. doi: 10.1155/2012/639748. Epub 2012 Jul 11.
Introduction. The objective of this study was to evaluate Ki-67 antigen expression in patients with Barrett's esophagus and esophageal adenocarcinoma and to assess its correlation with the metaplasia-esophageal adenocarcinoma progression. Methods. Using immunohistochemistry we evaluated the Ki-67 index in patients with Barrett's esophagus, esophageal adenocarcinoma, and controls. We included patients with endoscopically visible columnar mucosa of the distal esophagus (whose biopsies revealed specialized intestinal-type metaplasia), patients with esophageal and esophagogastric tumors types I and II, and patients with histologically normal gastric mucosa (control). Results. In the 57 patients studied there were no statistically significant differences between the groups with respect to age or race. Patients with cancer were predominantly men. The Ki-67 index averaged 10 ± 4 % in patients with normal gastric mucosa (n = 17), 21 ± 15 % in patients with Barrett's esophagus (n = 21), and 38 ± 16 % in patients with cancer (n = 19). Ki-67 expression was significantly different between all groups (P < 0.05). There was a strong linear correlation between Ki-67 expression and the metaplasia-adenocarcinoma sequence (P < 0.01). In patients with cancer, Ki-67 was not associated with clinical or surgical staging. Conclusions. Ki-67 antigen has increased expression along the metaplasia-adenocarcinoma sequence. There is a strong linear correlation between Ki-67 proliferative activity and Barrett's carcinogenesis.
简介。本研究的目的是评估 Ki-67 抗原在 Barrett 食管和食管腺癌患者中的表达，并评估其与化生-腺癌进展的相关性。方法。我们使用免疫组织化学方法评估了 Barrett 食管、食管腺癌和对照组患者的 Ki-67 指数。我们纳入了经内镜可见的远端食管柱状黏膜（活检显示特异性肠型化生）、食管和食管胃肿瘤 I 型和 II 型以及组织学正常胃黏膜的患者（对照组）。结果。在 57 名研究患者中，各组在年龄或种族方面无统计学差异。癌症患者主要为男性。正常胃黏膜患者的 Ki-67 指数平均为 10 ± 4%（n = 17），Barrett 食管患者为 21 ± 15%（n = 21），癌症患者为 38 ± 16%（n = 19）。Ki-67 表达在所有组之间均有显著差异（P < 0.05）。Ki-67 表达与化生-腺癌序列之间存在强烈的线性相关性（P < 0.01）。在癌症患者中，Ki-67 与临床或手术分期无关。结论。Ki-67 抗原在化生-腺癌序列中表达增加。Ki-67 增殖活性与 Barrett 癌发生之间存在强烈的线性相关性。
